<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01195207</url>
  </required_header>
  <id_info>
    <org_study_id>CR017095</org_study_id>
    <nct_id>NCT01195207</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of CNTO 3157 in Healthy Volunteers and Patients With Asthma</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Intravenous Study in Healthy Subjects and a Multiple-Dose Intravenous Study in Asthmatic Subjects to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of CNTO 3157</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centocor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centocor, Inc.</source>
  <brief_summary>
    <textblock>
      This is a phase 1, safety study of CNTO 3157 in healthy subjects and subjects with asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase 1, randomized (study drug assigned by chance), double blind (neither physician nor
      patient knows if CNTO 3157 or placebo has been assigned), placebo controlled, single,
      ascending-dose study of CNTO 3157 in healthy volunteers and multiple dose study in patients
      with asthma. This study will compare the effects (both good and bad) of CNTO 3157 to those of
      placebo. The purpose of this study is to evaluate the safety and potential side effects of
      CNTO 3157 given to healthy volunteers and patients with asthma. In addition, the
      investigators will measure how much study drug is in the blood following a dose of CNTO 3157,
      and determine if the body makes antibodies to it. (An antibody is a protein made by the body
      in response to a foreign substance). Safety assessments will be performed throughout the
      study and include obtaining and evaluating laboratory tests, vital signs (e.g., blood
      pressure), and the occurrence and severity of adverse events. There will be 2 parts to this
      study. The first part of this study will involve healthy volunteers, and the second part of
      the study will involve patients with asthma. About 56 healthy volunteers and 16 asthmatic
      patients will take part. Volunteers will be required to stay at the research center after
      study agent administration for an inpatient portion of the study and then return for required
      out-patient visits. Up to approximately 8 different dose levels will be studied. CNTO 3157
      will be administered by IV infusion. The duration of volunteer participation will be up to 21
      weeks in Part 1 and up to 24 weeks in Part 2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of CNTO 3157 by evaluating laboratory tests, vital signs (e.g., blood pressure), and the occurrence and severity of adverse events</measure>
    <time_frame>Week 21 for Part 1 and Week 24 for Part 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effects of CNTO3157 on the body and the effects of the body on CNTO 3157 (Pharmacokinetics (PK), Pharmacodynamics (PD))</measure>
    <time_frame>Week 21 for Part 1 and Week 24 for Part 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response (Immunogenicity)</measure>
    <time_frame>Week 21 for Part 1 and Week 24 for Part 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response</measure>
    <time_frame>Week 21 for Part 1 and Week 24 for Part 2</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNTO 3157 or placebo 0.003 mg/kg CNTO 3157 or placebo infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNTO 3157 or placebo 0.01 mg/kg CNTO 3157 or placebo infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNTO 3157 or placebo 0.03 mg/kg CNTO 3157 or placebo infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNTO 3157 or placebo 0.1 mg/kg CNTO 3157 or placebo infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNTO 3157 or placebo 0.3 mg/kg CNTO 3157 or placebo infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>006</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNTO 3157 or placebo 1 mg/kg CNTO 3157 or placebo infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>007</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNTO 3157 or placebo 3 mg/kg CNTO 3157 or placebo infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>008</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNTO 3157 or placebo 10 mg/kg CNTO 3157 or placebo infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CNTO 3157 or placebo</intervention_name>
    <description>0.003 mg/kg CNTO 3157 or placebo infusion</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CNTO 3157 or placebo</intervention_name>
    <description>0.03 mg/kg CNTO 3157 or placebo infusion</description>
    <arm_group_label>003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CNTO 3157 or placebo</intervention_name>
    <description>10 mg/kg CNTO 3157 or placebo infusion</description>
    <arm_group_label>008</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CNTO 3157 or placebo</intervention_name>
    <description>0.01 mg/kg CNTO 3157 or placebo infusion</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CNTO 3157 or placebo</intervention_name>
    <description>1 mg/kg CNTO 3157 or placebo infusion</description>
    <arm_group_label>006</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CNTO 3157 or placebo</intervention_name>
    <description>3 mg/kg CNTO 3157 or placebo infusion</description>
    <arm_group_label>007</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CNTO 3157 or placebo</intervention_name>
    <description>0.3 mg/kg CNTO 3157 or placebo infusion</description>
    <arm_group_label>005</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CNTO 3157 or placebo</intervention_name>
    <description>0.1 mg/kg CNTO 3157 or placebo infusion</description>
    <arm_group_label>004</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female between 18 and 55 years of age inclusive with no clinically
             significant abnormalities and have a body weight of 50 to 100 kg

          -  Patients with asthma must have been diagnosed at least 6 months prior to participation
             in the study

        Exclusion Criteria:

          -  Currently have or have a history of any clinically significant medical illness or
             medical disorders the investigator considers should exclude the subject, including
             (but not limited to) cardiovascular disease, neuromuscular, hematological disease,
             immune deficiency state, respiratory disease (other than asthma for Part 2), hepatic
             or GI disease, neurological or psychiatric disease, ophthalmological disorders,
             neoplastic disease, renal or urinary tract diseases, or dermatological disease

          -  Have a positive pregnancy test at screening or prior to dose administration

          -  Have smoked tobacco or related products within 6 months prior to dosing

          -  Donated blood equal to or greater than Â¿450 mL within 60 days prior to participation
             in the study

          -  Recent history (within previous 6 months) of alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Centocor, Inc. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Centocor, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merksem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harrow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2010</study_first_submitted>
  <study_first_submitted_qc>September 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2010</study_first_posted>
  <last_update_submitted>November 22, 2012</last_update_submitted>
  <last_update_submitted_qc>November 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CNTO 3157</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

